Consequently, the impact of targeting FABP4 on the overall pathogenesis of COVID-19, and the protection that such interventions may offer to individuals with underlying metabolic conditions, may not be limited to the reduction in viral titers. This evidence concerns the gene FABP4 and COVID-19.